GlassScriptPhysician profile
John W Dubay
NPI 1033137518
$1,507.41
in general payments reported to CMS, 2019-2025
29 companies · $644 in 2025
The $644 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $225 · 2021: $195 · 2022: $42.42 · 2024: $70.88 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $714.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $306.11 | 2019-2025 | Keytruda, Lynparza |
| Delcath Systems | $235.43 | 2025 | Hepzato Kit |
| Caris Mpi, INC. | $157.01 | 2025 | Mi Cancer Seek |
| E.R. Squibb & Sons, L.L.C. | $112.27 | 2019-2025 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $79.74 | 2019-2021 | |
| Janssen Biotech, INC. | $73.20 | 2019-2025 | Carvykti, Rybrevant |
| Pharmacyclics LLC, An Abbvie Company | $68.98 | 2021-2022 | |
| Pfizer INC. | $49.79 | 2019-2021 | |
| Celgene Corporation | $48.47 | 2019-2021 | |
| Glaxosmithkline, LLC. | $44.31 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $37.25 | 2019-2020 | |
| Kite Pharma, INC. | $29.43 | 2021 | |
| Secura Bio, INC. | $27.91 | 2020 | |
| Myriad Genetic Laboratories, INC. | $26.68 | 2021 | |
| Iovance Biotherapeutics, INC. | $23.52 | 2025 | Amtagvi |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $21.43 | 2025 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $19.08 | 2025 | Imfinzi |
| Stemline Therapeutics INC. | $16.75 | 2020 | |
| Genzyme Corporation | $16.73 | 2019 | |
| Amgen INC. | $16.36 | 2019 | |
| Astellas Pharma US INC | $16.06 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $14.96 | 2021 | |
| Tersera Therapeutics LLC | $14.02 | 2020 | |
| Lilly USA, LLC | $13.82 | 2019 | |
| Incyte Corporation | $13.59 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.59 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dubay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.